Target intelligence / Profile preview

Tumor necrosis factor alpha-induced protein 1 (TNFAIP1)

Target
TNFAIP1
Molecular classification
Adapter protein, E3 ubiquitin ligase complex component, BTB/POZ domain-containing protein
01

Overview

Tumor necrosis factor alpha-induced protein 1 (TNFAIP1) is a BTB/POZ domain-containing adapter protein that functions as a substrate-specific adapter within a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex, particularly mediating the ubiquitination and proteasomal degradation of RhoA, a small GTPase involved in cytoskeletal dynamics and cell migration[2][6]. TNFAIP1 is inducible by tumor necrosis factor alpha (TNF-α), has regulatory roles in cytoskeleton maintenance, cell migration, DNA synthesis, and DNA repair through interaction with PCNA and DNA polymerase delta. TNFAIP1 is implicated in cancer biology, being overexpressed in several cancer types and associated with adverse prognosis, notably in lung cancer. It may play roles in other conditions, such as neurodevelopmental disorders, but current data primarily support its importance in cellular homeostasis and cancer progression[1][2][6].

Other names
BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2BACURD2EDP1hBACURD2B61B12MGC2317BTBD34BTB/POZ domain-containing protein TNFAIP1Protein B12Tumor necrosis factor, alpha-induced protein 1 (endothelial)Tumor necrosis factor, alpha induced protein 1
02

Mechanism of action

For drugs targeting upstream regulatory pathways (not TNFAIP1 itself): Inhibition of neddylation leads to accumulation of TNFAIP1 by preventing its degradation via the ubiquitin-proteasome system[1].

03

Biological functions

Regulation of cytoskeleton structureProtein polyubiquitinationCell migrationDNA synthesisDNA repairRegulation of apoptosis
04

Disease associations

CancerPontocerebellar hypoplasia type 16Potential roles in neurodegeneration and development (based on gene expression)
05

Safety considerations

No specific safety concerns for direct targeting of TNFAIP1 have been reported; however, manipulating ubiquitin-proteasome or neddylation pathways can cause broad effects including cytotoxicity and immune modulation due to their essential roles in cellular protein homeostasis[1].
06

Interacting drugs

MLN4924 (pevonidistat)
07

Biomarkers

Overexpression of TNFAIP1 is associated with poor survival in lung cancer, suggesting use as a biomarker for prognosis in specific cancer types[1].

Beyond the preview

Go deeper on Tumor necrosis factor alpha-induced protein 1 (TNFAIP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor alpha-induced protein 1 (TNFAIP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call